USA Today · Jul 2026
Mainstream consumer coverage describing FODZYME as an attention-getting option for people with IBS/FODMAP sensitivities and explaining how the powder works on food before digestion.
Patent-pending enzymes to break down common dietary triggers
Company research
Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Overview
Kiwi Biosciences is the company behind FODZYME®, a patent-pending enzyme powder for FODMAP-related digestive symptoms. It sells primarily as a consumer health supplement, with additional clinician/provider distribution and support resources.
Primary product
FODZYME®
Founded
2020
Headquarters
Cambridge, Massachusetts, United States
Team size
10-20
Work style
Flexible
Industry
Biotechnology
Sub-industry
digestive health enzyme supplements
Offices
Cambridge, Massachusetts, United States
Open Positions
0 jobs at Kiwi Biosciences
No open positions
Check back later for new openings